Produção Nacional
Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis
2017; Elsevier BV; Volume: 57; Linguagem: Inglês
10.1016/j.rbre.2017.07.001
ISSN2255-5021
AutoresSebastião Cézar Radominski, Wanderley Marques Bernardo, Ana Patrícia de Paula, Ben‐Hur Albergaria, Caio Moreira, César Eduardo Fernandes, Charlles Heldan de Moura Castro, Cristiano A. F. Zerbini, Diogo Souza Domiciano, Laura Maria Carvalho de Mendonça, Luciano de Melo Pompei, Mailze Campos Bezerra, Marco Antonio Rocha Loures, Maria Celeste Osório Wender, Marise Lazaretti‐Castro, Rosa Maria Rodrigues Pereira, Sérgio Setsuo Maeda, Vera Lúcia Szejnfeld, Victoria Borba,
Tópico(s)Bone health and treatments
ResumoOsteoporosis is the leading cause of fractures in the population older than 50 years. This silent disease affects primarily postmenopausal women and the elderly, and the morbidity and mortality rates are high. The main goal of treating osteoporosis is the prevention of fractures. The identification of populations at risk through early diagnosis and treatment is essential. The last Brazilian guideline for the treatment of postmenopausal osteoporosis was elaborated in 2002. Since then, new strategies for diagnosis and risk stratification have been developed, and drugs with novel action mechanisms have been added to the therapeutic arsenal. The Osteoporosis and Osteometabolic Diseases Committee of the Brazilian Society of Rheumatology, in conjunction with the Brazilian Medical Association and other Societies, has developed this update of the guidelines for the treatment of postmenopausal osteoporosis according to the best scientific evidence available. This update is intended for professionals in many medical and health specialties involved in the treatment of osteoporosis, for physicians in general and for health-related organizations.
Referência(s)